Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up

Elias Jabbour • 24 Nov 2025
ASH 2025
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab

Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I/II dose-expansion study (NCT04521231) evaluating the efficacy of single-agent subcutaneous (SC) blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Dr Jabbour highlights the advantages of this route of administration, including convenience and the ability to deliver higher doses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elias Jabbour

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Elias Jabbour • 24 Nov 2025
T-cell engagers and treating relapsed ALL
T-cell engagers and treating relapsed ALL
Elias Jabbour • 29 Sep 2022
Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL
1:03
Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL
Elias Jabbour • 10 Dec 2023
Obe-cel for R/R B-ALL: pooled analysis of the ongoing FELIX study
1:26
Obe-cel for R/R B-ALL: pooled analysis of the ongoing FELIX study
Elias Jabbour • 10 Dec 2023

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Elias Jabbour • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Elias Jabbour • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Elias Jabbour • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Elias Jabbour • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals